Insight Molecular Diagnostics Return on Tangible Equity 2014-2025 | IMDX
Current and historical return on tangible equity values for Insight Molecular Diagnostics (IMDX) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Insight Molecular Diagnostics Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2025-03-31 | $-0.06B | $0.00B | 210.71% |
| 2024-12-31 | $-0.06B | $-0.03B | 159.48% |
| 2024-09-30 | $-0.04B | $-0.05B | 108.64% |
| 2024-06-30 | $-0.04B | $-0.03B | 113.43% |
| 2024-03-31 | $-0.04B | $-0.05B | 145.13% |
| 2023-12-31 | $-0.03B | $-0.04B | 133.33% |
| 2023-09-30 | $-0.06B | $-0.02B | 292.31% |
| 2023-06-30 | $-0.06B | $-0.01B | 269.66% |
| 2023-03-31 | $-0.06B | $-0.02B | 237.62% |
| 2022-12-31 | $-0.07B | $-0.03B | 217.91% |
| 2022-09-30 | $-0.06B | $-0.03B | 209.84% |
| 2022-06-30 | $-0.07B | $-0.03B | 261.54% |
| 2022-03-31 | $-0.07B | $-0.05B | 297.87% |
| 2021-12-31 | $-0.06B | $-0.02B | -3657.14% |
| 2021-09-30 | $-0.03B | $-0.01B | -438.71% |
| 2021-06-30 | $-0.03B | $-0.02B | -203.77% |
| 2021-03-31 | $-0.03B | $0.05B | -125.30% |
| 2020-12-31 | $-0.03B | $0.01B | -260.87% |
| 2020-09-30 | $-0.03B | $0.01B | -188.24% |
| 2020-06-30 | $-0.03B | $0.02B | -137.93% |
| 2020-03-31 | $-0.03B | $0.01B | -98.11% |
| 2019-12-31 | $-0.02B | $0.03B | -66.67% |
| 2019-09-30 | $-0.02B | $0.03B | -73.08% |
| 2019-06-30 | $-0.02B | $0.03B | -81.93% |
| 2019-03-31 | $-0.02B | $0.04B | -121.43% |
| 2018-12-31 | $-0.02B | $0.00B | -261.54% |
| 2018-09-30 | $-0.02B | $0.01B | -237.04% |
| 2018-06-30 | $-0.02B | $0.01B | -307.69% |
| 2018-03-31 | $-0.02B | $0.01B | -316.67% |
| 2017-12-31 | $-0.02B | $0.00B | -333.33% |
| 2017-09-30 | $-0.02B | $0.01B | -262.07% |
| 2017-06-30 | $-0.02B | $0.01B | -176.47% |
| 2017-03-31 | $-0.01B | $0.01B | -175.00% |
| 2016-12-31 | $-0.01B | $0.01B | -160.00% |
| 2016-09-30 | $-0.01B | $0.01B | -173.33% |
| 2016-06-30 | $-0.01B | $0.00B | -266.67% |
| 2016-03-31 | $-0.01B | $0.01B | -266.67% |
| 2015-12-31 | $-0.01B | $0.01B | -355.56% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.075B | $0.002B |
| Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $45.259B | 57.58 |
| Doximity (DOCS) | United States | $11.613B | 51.53 |
| Hims & Hers Health (HIMS) | United States | $11.187B | 92.56 |
| Tempus AI (TEM) | United States | $10.529B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $5.158B | 0.00 |
| Hinge Health (HNGE) | United States | $4.347B | 0.00 |
| Privia Health (PRVA) | United States | $2.493B | 184.64 |
| Inspire Medical Systems (INSP) | United States | $2.355B | 34.62 |
| Phreesia (PHR) | United States | $1.614B | 0.00 |
| Enovis (ENOV) | United States | $1.607B | 8.49 |
| 10x Genomics (TXG) | United States | $1.516B | 0.00 |
| Omnicell (OMCL) | United States | $1.416B | 27.28 |
| Schrodinger (SDGR) | United States | $1.367B | 0.00 |
| Azenta (AZTA) | United States | $1.283B | 55.96 |
| Clover Health Investments (CLOV) | United States | $1.257B | 0.00 |
| Evolent Health (EVH) | United States | $1.082B | 0.00 |
| Claritev (CTEV) | United States | $1.013B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.631B | 0.00 |
| Veradigm (MDRX) | United States | $0.503B | 0.00 |
| Standard BioTools (LAB) | United States | $0.486B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.461B | 0.00 |
| Talkspace (TALK) | United States | $0.412B | 123.00 |
| Carlsmed (CARL) | $0.346B | 0.00 | |
| Butterfly Network (BFLY) | United States | $0.342B | 0.00 |
| TruBridge (TBRG) | United States | $0.288B | 50.50 |
| Nyxoah SA (NYXH) | Belgium | $0.239B | 0.00 |
| Outset Medical (OM) | United States | $0.221B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.203B | 0.00 |
| CapsoVision (CV) | United States | $0.190B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.188B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.187B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.136B | 0.00 |
| American Well (AMWL) | United States | $0.112B | 0.00 |
| CareCloud (CCLD) | United States | $0.108B | 4.92 |
| EUDA Health Holdings (EUDA) | Singapore | $0.094B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.088B | 0.00 |
| Pulmonx (LUNG) | United States | $0.063B | 0.00 |
| 111 (YI) | China | $0.059B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.047B | 0.00 |
| HeartBeam (BEAT) | United States | $0.032B | 0.00 |
| Zhongchao (ZCMD) | China | $0.024B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.023B | 0.00 |
| Precipio (PRPO) | United States | $0.021B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.018B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.013B | 0.00 |
| HeartSciences (HSCS) | United States | $0.008B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.008B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.007B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.006B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.005B | 0.00 |
| Movano (MOVE) | United States | $0.004B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
| PROFUSA (PFSA) | United States | $0.003B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |